| Literature DB >> 35189976 |
Shohra Qaderi1, Hossein Hatami2, Ahmad Murad Omid3, Jalal Sayad3.
Abstract
BACKGROUND: Crimean-Congo hemorrhagic fever is a severe vector-borne viral hemorrhagic fever with considerable mortality in humans. This disease is endemic in Afghanistan, and its incidence rate has rapidly increased in recent years. This infection can cause a broad range of hemorrhage manifestations including epistaxis, petechial or purpuric rashes, hematemesis, and melena; however, vaginal bleeding is also reported as a rare manifestation. CASEEntities:
Keywords: Afghanistan; Crimean–Congo hemorrhagic fever (CCHF); Uterine bleeding
Mesh:
Substances:
Year: 2022 PMID: 35189976 PMCID: PMC8862576 DOI: 10.1186/s13256-022-03303-z
Source DB: PubMed Journal: J Med Case Rep ISSN: 1752-1947
Laboratory data*
| Variables | Reference range | Hospital range |
|---|---|---|
| Blood | ||
| Hemoglobin (g/dl) | 12–15 | 10 |
| Hematocrit (%) | 36–45 | 38.4 |
| White-cell count (per mm3) | 4–11 | 2300 |
| Platelet count (per mm3) | 150–400 | 10,000 |
| Alanine aminotransferase (U/L) | 0–40 | 1318 |
| Aspartate aminotransferase (U/L) | 0–40 | 1921 |
| Total bilirubin (mg/dl) | < 1.2 | 2.2 |
| Direct bilirubin (mg/dl) | 1 | |
| Indirect bilirubin (mg/dl)β | 1.2 | |
| Prothrombin-time international normalized ratio | 0.9–1.1 | 3 |
| Urine | ||
| Color | Yellow | Dark |
| Clarity | Clear | |
| Specific gravity | 1.033 | 1.000 |
| pH | 7 | 7.2 |
| Protein | 2+ | |
| White cells per high-power field | 2+ | |
| Red cells per high-power field | 3+ | |
*All these tests were carried out in Antani’s hospital laboratory.
mg/dl: Milligram Per Decilitre
βWe obtained indirect bilirubin via total bilirubin − direct bilirubin
Treatment*
| Intervention | Dose/frequency | First day | Second day | Third day | Fourth day | Fifth day | Sixth day | Seventh day | Eighth day |
|---|---|---|---|---|---|---|---|---|---|
| Pantoprazole | 40 mg once | Yes | Yes | Yes | Yes | Yes | No | No | No |
| Ringer lactate | 1000 cc once | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Cefotaxime | 2 g three times daily | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Ribavirin | 2000 mg/once | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Platelet mass | 400 cc once | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
*Treatment received by patient over 8 days of hospitalization. Ribavirin 400 mg daily for two more 2 days and cefotaxime 1 g daily were prescribed as home treatment
Daily vital signs
| Days of admission | First | Second | Third | Fourth | Fifth | Sixth | Seventh | Eighth |
|---|---|---|---|---|---|---|---|---|
| Blood pressure (systole/diastole, mmHg) | 70/50 | 87/50 | 100/60 | 110/70 | 100/60 | 100/70 | 110/60 | 110/70 |
| RR (per minute) | 20 | 20 | 20 | 20 | 22 | 20 | 22 | 20 |
| PR (per minute) | 78 | 92 | 88 | 82 | 80 | 84 | 74 | 74 |
| T (°C) | 38 | 37.6 | 37.4 | 37.2 | 37.3 | 37 | 37 | 37 |
RR respiratory rate, PR pulse rate. T temperature